Organogenesis Holdings Stock (NASDAQ: ORGO)

Organogenesis Holdings

Organogenesis Hldgs

Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.

movers image

News

Intraday Update

Markets

Movers

Trading Ideas

AMPS

CAVA

DAVE

HNST

JBLU

JTAI

NTRA

ORGO

RIVN

RKLB

SPOT

TSEM

Paymentus Posts Better-Than-Expected Earnings, Joins Dave, Honest Company, Natera, CAVA Group And Other Big Stocks Moving Higher On Wednesday

Pre-Market Outlook

CDNA

HSHP

JFIN

LSEA

QRTEB

CareDx, JD.com And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

Macro,Shot,Of,Computer,Monitor,With,World,Stock,Market,Chart

ACIC

ADMA

AEHL

AFRM

AKAM

ARRY

ARWR

BFRI

BROS

CLNE

DCBO

DIOD

EVLV

FLNC

FLUX

FNKO

FROG

FWRD

GRPN

GRTS

GWAV

HGAS

INSG

IOVA

ITOS

LIDR

MGNX

MLTX

MVIS

NGVC

NVAX

NVTS

OUST

PEGY

PGNY

RVNC

RWAY

SKIN

SKYT

SOUN

SRTS

YELP

Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Organogenesis Holdings Inc

Health Care

Press Releases

Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September

Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024

General

Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock

Earnings

Organogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results

Financing

Organogenesis Commends Final LCDs

Organogenesis Expands Manufacturing Capacity to Support Future Growth

Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025

Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results

Akebia Therapeutics

AnaptysBio

ArriVent BioPharma

Bicara Therapeutics

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

Cogent Biosciences

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Immunome

Immatics

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharma

Keros Therapeutics

Kura Oncology

LENZ Therapeutics

MeiraGTx Hldgs

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

PureTech Health plc - American Depositary Shares

PureTech Health

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Replimune Group

Sage Therapeutics

Sionna Therapeutics

Savara

Tyra Biosciences

Valneva

Morgan Stanley

Lake Street

Cantor Fitzgerald

BTIG

Comments

Organogenesis Holdings

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga